Last updated: February 13, 2026
What is the drug associated with NDC 54482-0147?
The NDC 54482-0147 corresponds to Ibrutinib, marketed under the brand name Imbruvica. It is a kinase inhibitor used primarily for treating certain hematological malignancies, including mantle cell lymphoma, chronic lymphocytic leukemia, Waldenström's macroglobulinemia, and marginal zone lymphoma.
What is the current market landscape?
Market Size and Growth
- Global oncology drug market was valued at approximately USD 150 billion in 2021.
- Expected to grow at a 7.5% compound annual growth rate (CAGR) from 2022 to 2028, driven by increasing adoption of targeted therapies such as Ibrutinib and expanding indications.
- The U.S. accounts for over 45% of this market, with the value estimated at USD 70 billion in 2021.
Competitive Environment
- Key competitors include acalabrutinib (Calquence) and zanubrutinib (Brukinsa), both targeting similar indications.
- Ibrutinib’s market share remains dominant due to its first-to-market status, with approximately 70% of the BTK inhibitor segment.
- Patent expirations for Ibrutinib are expected around 2025–2027, risking generic entry and market share erosion.
Pricing and Reimbursement
- List price in the U.S.: approximately USD 13,000 per 30-day supply.
- Actual payer prices vary; negotiated discounts and rebates can reduce net prices by 20-40%.
- Insurance coverage is widespread for approved indications, with high patient access levels; however, copay assistance programs are common.
How are prices expected to change?
Short-term projections (1–2 years)
- List prices are likely to remain stable but actual net prices will decline due to rebates and discounts.
- Introduction of biosimilars or generics post-2025 is expected to depress prices by 15–30% within the subsequent 2 years after patent expiry.
Long-term projections (3–5 years)
- For the period post-patent expiration, generic versions could reduce drug prices significantly.
- Innovator prices may decline 40–60% if multiple generics enter the market, similar to other targeted oncology therapies once patents expire.
- Manufacturers may attempt to sustain higher prices through new indications, combination therapies, or formulation improvements like extended-release versions.
Regulatory and policy factors influencing price
- Price increases in the U.S. are limited by federal and state regulations, including Medicare pharmacy caps.
- Value-based pricing initiatives could tie reimbursement rates to clinical outcomes, potentially reducing overall drug expenditure.
- Negotiations for drug prices through Medicaid and private payers are increasingly common, impacting list prices.
What are the potential market entry points and risks?
Entry points
- Biosimilar or generic versions likely entering by 2025–2027.
- Expansion into new indications such as autoimmune diseases.
- Combination therapies with other targeted agents.
Risks
- Patent litigation delays or invalidation could accelerate generic entry.
- Market shifts away from small-molecule kinase inhibitors toward antibody-based or cell therapies.
- Regulatory hurdles in emerging markets could restrict access or delay penetration.
Summary table: Price and market projections
| Time Frame |
Price Trend |
Market Share Dynamics |
Key Factors |
| 2023–2024 |
Stable list prices; net prices decline via rebates |
Dominant market position, steady sales volume |
Patent protection, limited generic competition |
| 2025–2027 |
Patent expires; generic entry begins |
Potential erosion of market share by 30–50% |
Patent expiry, biosimilar approvals |
| 2028–2032 |
Further generic penetration; price decline |
Market becomes more price-sensitive, competition intensifies |
Biosimilar availability, alternative therapies |
Key Takeaways
- NDC 54482-0147 (Ibrutinib) maintains a leading market position due to first-mover advantage.
- List prices hover around USD 13,000/month, with net prices subject to discounts.
- Prices are projected to decline post-patent expiry, with generic versions triggering a 40–60% reduction.
- Market growth driven by expanding indications and unmet needs, but competitive pressures loom.
- Policy and regulatory developments may influence pricing strategies and reimbursement levels.
FAQs
1. When will generics of Ibrutinib likely enter the market?
Patent protection is expected to expire around 2025–2027, enabling generic or biosimilar entry shortly thereafter.
2. How will biosimilar competition affect Ibrutinib prices?
Biosimilars could reduce prices by 15–30% initially, with further declines following increased market penetration and multiple entrants.
3. What are the main drivers of future price reductions?
Patent expiration, increased competition, and biosimilar availability are primary factors influencing future price declines.
4. Are there emerging therapies that could impact Ibrutinib’s market share?
Yes; antibody-based therapies, CAR-T cells, and combination regimens are potential competitors, especially for resistant or broader indications.
5. How do reimbursement policies influence drug pricing?
Government and private payers are implementing value-based agreements, which could lead to price adjustments based on real-world outcomes.
Citations
[1] Market data sourced from Grand View Research, 2022.
[2] Pricing insights derived from Red Book and SSR Health, 2022.
[3] Competitive landscape summarized from EvaluatePharma, 2022.
[4] Patent expiry information aligned with patent databases, 2022.
